Opus Genetics (IRD) Return on Capital Employed (2018 - 2026)
Opus Genetics (IRD) reported Return on Capital Employed of 87.51% for Q1 2026, up 26453.0% year-over-year from N/an in Q1 2025, and up 19.74% on a QoQ basis from 109.03% in Q4 2025.
Opus Genetics (IRD) has 9 years of Return on Capital Employed data on file, last reported at 87.51% in Q1 2026.
- Quarterly Return on Capital Employed rose 26453.0% year-over-year to 87.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 87.51% (up 26453.0% YoY) and the FY2025 annual result came in at 107.9%, up 7408.0% from the prior year.
- Return on Capital Employed grew to 87.51% in Q1 2026 per IRD's latest filing, from 109.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 64.73% in Q3 2023 and bottomed at 784.63% in Q3 2025.
- The 5-year median for Return on Capital Employed is 87.51% (2026), against an average of 129.66%.
- The widest annual swing landed in 2025, when Return on Capital Employed slumped 70393 bps; it then surged 26453 bps in 2026.
- Tracing IRD's Return on Capital Employed over 5 years: stood at 62.79% in 2022, then slumped by 134 bps to 21.11% in 2023, then sank by 976 bps to 227.12% in 2024, then jumped by 52 bps to 109.03% in 2025, then gained by 20 bps to 87.51% in 2026.
- Per Business Quant, the three latest IRD Return on Capital Employed figures stand at 87.51% (Q1 2026), 109.03% (Q4 2025), and 784.63% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -87.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.51% |
| Dec 31, 2025 | -109.03% |
| Sep 30, 2025 | -784.63% |
| Jun 30, 2025 | -279.34% |
| Mar 31, 2025 | -352.04% |
| Dec 31, 2024 | -227.12% |
| Sep 30, 2024 | -80.70% |
| Jun 30, 2024 | -34.16% |
| Mar 31, 2024 | -25.77% |
| Dec 31, 2023 | -21.11% |
| Sep 30, 2023 | 64.73% |
| Jun 30, 2023 | 46.94% |
| Mar 31, 2023 | 43.22% |
| Dec 31, 2022 | 62.79% |
| Sep 30, 2022 | -163.44% |
| Jun 30, 2022 | -137.39% |
| Mar 31, 2022 | -119.73% |
| Dec 31, 2021 | -109.23% |
| Sep 30, 2021 | -141.63% |
| Jun 30, 2021 | -176.95% |
| Mar 31, 2021 | -178.01% |
| Dec 31, 2020 | -198.24% |
| Sep 30, 2020 | -14.25% |
| Jun 30, 2020 | -15.95% |
| Mar 31, 2020 | -63.80% |
| Dec 31, 2019 | 436.04% |
| Sep 30, 2019 | -106.34% |
| Jun 30, 2019 | -110.51% |
| Mar 31, 2019 | -122.10% |
| Dec 31, 2018 | -173.95% |